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Abstract
•

Next-generation sequencing of both DNA and RNA represents a second revolution in equine
genetics following publication of the equine genome sequence.

•

Technological advancements have resulted in a wide selection of next-generation sequencing
platforms capable of completing small targeted experiments or resequencing complete genomes.

•

DNA and RNA sequencing have applications in clinical and research environments.

•

Standards for the validation and sharing of next-generation sequencing data are critical for the
widespread application of the technology and applications discussed herein.

•

As researchers and clinicians develop a better understanding of how genetic variation and phenotypic variation are linked, next-generation sequencing could help pave the way to personalized
and precision management of horses.

Keywords: genomics, equine, RNA sequencing, transcriptome, genetic variation

Introduction
The sequencing and assembly of a reference genome for the horse has been revolutionary
for investigation of horse health and performance. Since its publication,1 the reference genome
has enhanced and accelerated genetic research in the horse, led to the development of new
ideas regarding management and precision medicine, and has led to the development of
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powerful tools that increased the scope and resolution of understanding the genetic underpinnings of equine physiology and disease pathology.2,3 The insights gained into equine
health as a result of these new tools and ideas are expertly reviewed in the accompanying
articles of this special issue. The advent and application of next-generation sequencing
(NGS) methods represent a second revolution for the study of equine genetics, enabling
researchers to exploit and explore the information encoded in the equine genome through
their experiments. NGS has also improved the ability of researchers to translate their discoveries into clinically relevant applications. This article provides an overview of the history and development of NGS, details some of the available sequencing platforms, and
describes currently available applications in the context of both discovery and clinical settings (Fig. 1).

Figure 1. Visual summary of the key points for NGS application in the horse in both discovery and clinical settings.

Building Genomic Resources for the Horse
The use of DNA sequencing to investigate the underlying cause of heritable conditions in
the horse dates to the early 1990s. At that time, before the development of an equine reference genome, genetic studies relied on the use of genomic information from other species
to inform the investigation for important traits of the horse. Major successes using that
approach include the identification of a missense mutation causative of hyperkalemic periodic paralysis in the quarter horse4 and lethal white overo syndrome in American Paint
Horses.5 In 1995, the scientific communities’ focus on generating genomic tools specific to
the horse incited the formation of the Horse Genome Project. Through this collaboration,
intentional and international partnerships were built across academic and industry institutions, resulting in the generation of comparative, linkage, and radiation hybrid maps of
the equine genome (reviewed in Chowdhary6).
The most notable advancement for equine genomics thus far dates to 2006 when the
National Human Genome Research Institute of the National Institutes of Health identified
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the horse as a species of priority for genome sequence assembly efforts. In 2007, a draft
reference equine genome was completed.1 This reference genome, named EquCab2, was
generated with sequencing data from a single thoroughbred mare, Twilight, resulting in
an assembly with approximately 6.8-fold coverage. The assembly of these data was complemented by additional sequence information (bacterial artificial chromosome sequencing) of Twilight’s half-brother, Bravo. At the time, the accuracy of Sanger sequencing and
availability of linkage and physical maps of the genome resulted in EquCab2 being one of
the highest-quality reference genomes of any agricultural species. The genome was estimated to be 2.7 billion base pairs (bp), with more than 20,000 protein-coding genes annotated in the initial effort.1 This resource served as the basis for the development of genomic
tools and discovery for the following decade with assays to detect genomic and transcriptomic variation in the horse2,3,7–9 anchored in EquCab2.
In 2018, a new reference assembly, still based primarily on the sequence of Twilight,
was released.10 This improved reference genome, EquCab3, was the product of new technologies for sequencing of longer reads, helping to characterize repetitive regions of the
genome. The EquCab3 assembly also incorporates data generated by methods that use
structural proximity of sequences to help build continuity (Chicago11 and HiC12 libraries).
Compared with EquCab2, EquCab3 has 90% fewer gaps, better coverage of GC-rich regions, which often include gene promoters; and more complete coverage of the transcriptome.10 EquCab3 now serves at the primary reference genome assembly for the horse and
should be used for the analysis of future sequence data. It continues to be improved
through additional efforts to annotate not only protein-coding regions, but noncoding
RNA as well as regulatory features.13 Both EquCab2 and EquCab3 are available through
the National Center for Biotechnology Information (NCBI), Ensembl, and University of
California Santa Cruz genome browser utilities.
Technology
The driving force behind many of the developments in equine genetics, including but not
limited to the reference genome sequence, has been ever-improving and increasingly accessible DNA sequencing technology. The advancing technologies are generally grouped
into distinct generations by the scientific community to recognize the transformational impact they have had on the understanding of genetics. The history and impact of each generation of sequencing technology have been reviewed in detail.14,15 This article presents a
brief overview of each sequencing generation and specifically how it has or can affect studies of the equine genome related to animal health.
The method used to generate the data for assembly of EquCab2, data that were also
used for EquCab3, was Sanger sequencing, first published in 1977.16 Still used for projects
concerning a single gene or small portion of DNA, Sanger sequencing produces a highquality sequence in long fragments. Sanger sequencing relies on the selective incorporation
of dideoxy nucleotides during elongation of the nascent DNA strand during in vitro DNA
replication. Fragments are then visualized using an electrophoretic system to identify each
nucleotide in sequence. This method, which can generate sequence fragments of about 800
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bp, may be limited in throughput but remains the gold standard for accuracy (reviewed in
Shendure and Ji17).
As researchers began to work to develop reference genome assemblies, increasing the
throughput of sequencing technologies became a priority. The motivation behind the rapidly
evolving technology was to improve access by increasing accuracy and data-generating
capacity while at the same time decreasing costs. NGS technologies were designed to increase the rate by which data were generated through platforms that allowed for multiple
sequence reads to be collected at 1 time and also by coupling the inclusion of labeled nucleotides with the step of reading their identity. Next-generation, or massively parallel,
sequencing, therefore, had an advantage in its ability to generate a significantly greater
amount of sequence data at 1 time, although read length was compromised compared with
that possible with Sanger sequencing. In the past 10 to 15 years, NGS has become a standard method used in questions regarding the evolution of the species, for discovery of variation associated with phenotypes of interest, for the identification of diversity among
individuals and breeds, and for identification of genome function associated with disease.
Sequencing Platforms
As sequencing technologies have advanced, sequencing platforms available to generate
data have expanded at an astounding rate. Ten years ago, there were only a few types of
instruments available; these were expensive and required significant laboratory resources
to deploy. At present, there is a wide selection of instruments tailored to generate anywhere from a small amount of targeted sequence data to massive amounts of sequence
data capable of characterizing an entire genome in a single experiment. The various platforms use different types of chemistry; those differences have been previously reviewed.18,19
Now there is an NGS platform for most any job. As this technology continues to become
more accessible and manageable, it enhances the opportunities for sequencing and its
many applications to find their way into clinical practice.
The available NGS platforms can be classified into 3 main groups: production, benchtop, and portable systems. The choice of which platform to use depends on several variables of interest, the overall throughput needed, the accuracy of base calls, read length,
speed of data generation, and budget. Each platform category is described briefly in the
following paragraphs and is summarized in Table 1.
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Table 1. Comparison of production, benchtop, and portable next-generation sequencing platforms
System Scale
Production
Descriptors
Sequence output

Benchtop

Portable

Minimum

Maximum

Minimum

Maximum

Minimum

Maximum

7.5 Gbp

6 Tbp

1.2 Gbp

150 Gbp

1.8 Gbp

30 Gbp

Read output

0.5 M

20 B

4M

400 M

7M

12 M

Read length

50 bp

1 KB+

50 bp

1 KB+

—

10 Kb+

Platforms

Illumina HiSeq 4000
Illumina HiSeqX
Illumina NovaSeq 6000
PacBio Sequel/Sequel II
Oxford Nanopore
PromethION

Illumina MiSeq
Illumina NextSeq
Illumina iSeq 100
ThermoFisher Ion
S5/S5 XL
Oxford Nanopore
GridION

Oxford Nanopore
MinION
Oxford Nanopore
Flongle
Oxford Nanopore
SmidgION

Applications

Whole-genome
sequencing
Exome sequencing
Targeted sequencing
Epigenetic sequencing
DNA-protein
interactions
Transcriptome
sequencing
Gene expression
profiling
Small RNA sequencing

Targeted sequencing
Targeted expression
profiling
Small genome
sequencing
Small RNA sequencing

Small genome
sequencing
Targeted sequencing
Targeted expression
profiling
Epigenetic sequencing

Production systems represent the highest-throughput technology available and are targeted primarily for discovery and research applications. The designation of a production
system is derived from the idea that a researcher would need to produce a genome or
transcriptome sequence. Systems in this category have sufficient capacity to sequence an
entire genome in a single run (realistically many genomes given the coverage needed).
They are almost exclusively housed in core or service facilities because of the cost to purchase, deploy, and operate them. The advantage of these platforms is the output. One of
the highest-throughput systems currently available, the Illumina NovaSeq 6000, can generate 6 Tb of sequence data or 20 billion reads in less than 2 days (https://www.illumina
.com). This amount of data represents enough sequence to characterize the genome of 1
horse more than 300 times. More practically, this amount of data can be used to sequence
the genomes of 15 individual horses to coverage sufficient to confidently identify variation
unique to an individual in a single run. Other production-level systems, such as those from
Pacific Biosystems (https://www.pacb.com/) and Oxford Nanopore (https://nanoporetech
.com/) Technologies, produce significantly fewer reads per run than the Illumina systems.
Generating long-read output, the reads they produce are generally 10 to 100 times the size,
which increases their value for the assembly of complicated genomic or transcriptomic regions. However, long-read sequencing remains expensive for most purposes. At the time
of writing, whole-genome sequencing at approximately 15 times coverage using short-read
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technology can be generated at a core facility for approximately $500 per individual. Overall, these production systems increase sequencing capacity and improve accessibility for
researchers by reducing sample costs so that NGS technology can be applied effectively to
more research questions.
Benchtop systems represent the category of sequencers, which literally live in a laboratory on the benchtop. In general, they have moderate sequencing capacity (1.2–150 Gbp
sequence data and 4–400 million reads per run) but represent an improvement in accessibility for investigators. These instruments serve smaller communities of researchers (or
even a single laboratory) compared with the production systems. Therefore, benchtop systems often allow faster data generation because the researchers are not sharing the instrument with as many other users and do not have to wait as long to use the machine.
Examples of these include the Illumina MiSeq, iSeq 100, the ThermoFisher Ion Gene Studio
S5, and the Oxford Nanopore GridION. Benchtop systems are optimized for investigators
who have smaller sample sizes (e.g., preliminary studies), who wish to perform transcriptome analyses, which generally require lesser sequence output, or who have targeted sequencing objectives. These systems can also be used by those who want to use sequencing
in clinical medicine, although the applications for such sequencing are still developing.
Like much of technology, sequencers are becoming more efficient and are beginning to
come in much smaller packages. Portable systems are designed to allow sequencing without the requirement of the support of a full laboratory. Examples of these systems are currently available from Oxford Nanopore and include the MinION and SmidgION (a smallcapacity sequencer that can be operated with a smartphone). The amount of data generated
is impressive but generally lower than either the benchtop or production systems. Both
systems are supported by equally portable sample preparation and analysis tools. Possible
applications of these mobile systems include stall-side diagnoses of an infectious pathogen
or DNA verification of an individual’s identity. Analyses can be conducted in a short
amount of time to answer time-sensitive questions (e.g., what strain of a virus is present?).
Sequence Reads
Just as the number and type of available sequencers have proliferated, so too have the
types of data produced. The primary distinction of sequence data is the length of reads
generated by the sequencing instrument. There are 2 main categories for NGS data: short
and long reads. Short sequence reads (short reads) are usually shorter than 500 bp in
length, whereas long sequence reads (long reads) exceed 1000 bp.20 Sanger sequencing
reads are between these 2 classifications.
Short-read sequence is the most common type of NGS data reported in the literature.
The main advantage of short-read sequencing is that a single instrument can produce large
amounts of data with high-quality base calls in 1 run (see Table 1). This ability gives researchers/clinicians options for their sequencing experiments: they can generate high levels of coverage on a few individual samples to support identification of sequence variants
in DNA and characterization of gene expression (Table 2), or they can pool samples to
efficiently and cost-effectively generate data for large sample sets. Short reads can be classified as either single-end or paired-end. This designation refers to whether sequence was
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generated from both or just 1 end of the captured DNA fragments. Single-end short reads
are valuable for rapid and inexpensive characterization of DNA sequence or gene expression. However, their use is limited for the characterization of complex sequence regions
such as sequence repeats or alternative splicing. This limitation results from ambiguity in
aligning the single-end read back to a reference genome. The advantage of paired-end
reads is that sequence from both ends of a DNA fragment of known length is generated.
Then, information from both ends of the read can be used in parallel, which enhances the
strategies used to address characterization of complex sequences. Paired-end reads, which
align to the reference genome at a distance (between the reads) less than or greater to what
was expected, can indicate the presence of a sequence variant such as an insertion or deletion, or, in the case of transcriptome data, can reveal patterns of alternative splicing. Figure
2 shows both single-end and paired-end short reads and the application of those reads to
the characterization of DNA and RNA sequences.
Table 2. Summary of various next-generation sequencing application categories, including the
type of variants it is possible to assay and how much sequence data are required
Target

Category

Application/Detection

Coverage/Sequence Required

DNA

Genome sequencing
Exome sequencing
Targeted sequencing
Methylation
De novo assembly

SNPs, INDELs, CNVs,
genotyping
SNPs
ChIP, SNPs, chromosome
conformation
Bisulfite
SNPs, INDELs, CNVs,
genotyping

10× to 60× coverage
100× coverage
15–100 million reads
15–30 million reads
140× coverage

RNA

Transcriptome sequencing
Targeted Sequencing
De novo assembly

Differential expression, small
RNAs, alternative splicing
CLIP, transcript panels, tag
capture

10–100 million reads
5–40 million reads
> 100 million reads

Differential expression, small
RNAs, alternative splicing
Abbreviations: ChIP, chromatin immunoprecipitation; CLIP, cross-linking immunoprecipitation; CNVs, copy
number variations; INDELs, insertions/deletions; SNPs, single nucleotide polymorphisms
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Figure 2. Various read types and read lengths and the application of those reads for DNA
and RNA sequencing. In both cases, the reads are aligned to a reference genome (black
rectangle) for analysis. (A) DNA sequencing: the region of the genome depicted contains
2 copies of a repeated motif (green rectangles). Single-end short reads are aligned across
the genome at unique locations (blue rectangles) or multiple locations (red rectangles) if they
originated from a repeat sequence. Paired-end short reads (yellow rectangles joined by
dashed lines) can help to characterize the repeat regions because they align to the repeats
and are anchored by alignment to unique sequences. Long reads (large purple boxes) align
uniquely to the reference genome and can be used to characterize repeat sequence because
they span the entire region. (B) RNA sequencing: the area of the genome depicted encodes
a protein-coding gene (green boxes connected by solid lines). Single-end short reads map to
sequence representing the exonic regions of the gene and can be mapped with a gapped
alignment (light blue rectangles joined by angled solid lines) representing the union of 2 exons
by splicing. Paired-end short reads also align to the exonic regions of the gene and can be
used to define exon order in a transcript by linking multiple exons together. Long reads
can help determine full-length transcripts and can be used to separate overlapping transcript structures.

Long-read sequence data are increasing in popularity for NGS experiments. The instruments that generate these data generally produce fewer sequence reads per run, but the
reads they do provide are significantly longer than those from any short-read NGS platform (see Table 1). When first released, reads from these instruments averaged 1100 bp in
length. Improvements in chemistry quickly increased the expected read length to 10,000
bp, with some reads spanning 60,000 bp. Genome assembly and the investigation of largescale structural variation is aided by long-read sequencing because the long reads can
sometimes span the length of repetitive regions of the genome, or moderately sized insertions/deletions. The read length achievable has led to the preferential use of this platform
for genome assembly and scaffolding, as was the case in the newest assembly of the equine
genome, EquCab3.10 Long-read sequencing has also helped to resolve the structure and
sequence of highly repetitive regions such as the equine major histocompatibility complex.21
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Long sequence reads can also be used for annotation of alternative splicing in the transcriptome because the long reads can span entire transcripts. Figure 2 shows how long
reads can be used in both DNA and RNA sequencing (RNA-seq) applications. A common
strategy is to combine both short-read and long-read data in a single NGS experiment to
exploit the advantages offered by each.
Applications
With production instruments now capable of producing terabytes of data each run, the
sequencing of a horse’s entire genome is now arguably the most common use of NGS technologies. This type of sequencing can allow the identification of inherited or de novo variation associated with disease. Whole-genome sequencing in the horse has enabled the
discovery of variation that can be assayed to identify the risk of disease or for use in diagnosis. Some findings that resulted from the use of whole-genome sequence include missense variants causative of lavender foal syndrome,22 immune-mediated myositis,23 the
identification of a locus associated with risk for squamous cell carcinoma in Haflingers,24
a nonsense mutation associated with hydrocephalus in Friesians,25 a splice-site mutation
in Friesian horses with dwarfism,26 and a large deletion associated with occipitoatlantoaxial malformation.27 A practical alternative to whole-genome sequencing can be sequencing
of only the exome, the regions of the genome that code for the exons of protein-coding
genes. This approach requires that the exonic sequence is captured (either in solution or
on an array) to prepare the DNA for sequencing. Because the region to be sequenced is
reduced relative to the whole genome, this approach can enable a researcher to generate
sequence from a larger number of individuals. The primary limitation in horses is the availability of capture technology. Exome sequencing has been used in the horse to identify
variants relative to racing performance in quarter horses.28 In each of these examples, the
sequence generated was aligned to the reference genome and variants differing between
affected horses and the reference sequence, or compared with healthy controls, were identified. As part of this process, after variants that either fit the hypothesized mode of inheritance or are found in candidate genes are identified, the possible function of each can be
predicted using the genome annotation. In cases where genes may not be annotated, the
region can be aligned to orthologous loci of other species. The impact of genomic variants
on gene expression can also be assayed through RNA sequencing of the appropriate tissues.
The process of sequencing of the transcriptome (any portion of the DNA actively being
transcribed into RNA at the time the tissue is sampled) is similar to that of sequencing
DNA. The exception is an initial reverse transcription step, through which the isolated
RNA is converted to double-stranded, copy DNA. The library preparation method used
for RNA-seq depends on the question at hand. Poly-A+ selected libraries capture most messenger RNA and some long noncoding RNA, as long as a poly-A tail is present on the
transcript. Poly-A+ library preparation and paired-end sequencing are the most common
means to assess the expression of protein-coding loci. Differential expression can also be
assayed using 3′ tag-seq (Quantseq; Lexogen, Greenland, NH), a method in which libraries
are created for only the 3′ end of each RNA molecule present in the sample. Tag-seq does
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not allow the identification of gene isoforms, but, by focusing sequencing efforts on only
the terminal end of each transcript, differential expression analyses require significantly
lower sequencing depth (~6 million reads per sample)29,30 using single-end reads, therefore
reducing overall cost. As in whole-genome sequencing, reads from RNA-seq are mapped
to the reference genome or, in some cases, the transcriptome. In the horse, RNAseq data
have been used to develop and improve gene annotation.31–34 The relative abundance of
each transcript can then be quantified using the available gene annotation and compared
between treatments or disease states.35–39 The sequencing of mRNA through poly-A+ selection not only allows the quantification of each transcript but can provide insight into splicesite variation. Further, RNA libraries are often stranded, meaning the sequence generated
distinguishes the strand of DNA from which the transcript was derived. This technique is
a powerful method to identify and distinguish antisense transcripts. The advent of longread technology can also be applied to studies of the transcriptome. Iso-seq is the use of
PacBio sequencing, enabling the profiling of full-length RNA transcripts.40 This methodology
reduces 3′ sequencing bias, which is common in poly-A+ library preparation, and is a powerful means to annotate genomes and identify variation in codon usage. However, as a longread technology, Iso-seq is thus far too expensive for most clinical investigations. In contrast, Poly-A+ library preparation neglects sequencing of small RNAs such as microRNAs,
which can be assayed with a special, small RNA library preparation method. MicroRNAs
are small (21–25 nucleotides) RNA fragments encoded by the animal’s genome. Although
they do not function to create proteins, they can bind to and silence the expression of proteincoding genes; therefore, their activity in posttranscriptional modification can significantly
affect genome function.41 In horses, microRNA profiles have been proposed as useful biomarkers for infection42 or other disorders.43,44
In addition to the identification of genomic variants and the transcript expression, NGS
can be used to understand chemical modifications to the DNA, such as methylation, or to
identify regions of the genome interacting with protein. DNA methylation, a chemical
modification of cytosine to 5-methylcytosine, is a common epigenetic mechanism involved
in silencing gene expression.45 Although the inheritance of some epigenetic modifications,
such as DNA methylation, is not completely understood, like RNA-seq, examining methylation patterns can help to understand differences in gene regulation and expression between diseased and healthy individuals. Similar to chromatin immunoprecipitation (ChIP;
discussed later), genome-wide methylation can be assayed by using antibodies to precipitate DNA having 5-methylcytosine modifications; that DNA is then sequenced on a nextgeneration platform (MeDIP-seq).46 To the authors’ knowledge, this method has not yet been
applied in a case of equine disease research; however, this technique has been used to characterize changes in genomic methylation in equine skeletal muscle caused by exercise.47,48
ChIP is a method by which regions of the DNA involved in an interaction with protein
are isolated.49 Those regions of DNA can then be sequenced using standard next-generation
methodology (ChIP-seq), and the resulting DNA fragments aligned to the reference genome
to identify genomic regions involved in the interaction. Similarly, cross-linking immunoprecipitation (CLIP) is a method that enables the isolation of RNA transcripts specifically
interacting with a protein.50 The captured transcripts can be sequenced (CLIP-seq) to identify regulatory aspects of gene expression. Sequence variants in the regions of interaction
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can alter binding efficiency and thus function. In addition, alteration in protein-DNA or
protein-RNA interactions can uncover functional information regarding molecular mechanisms of disease. Therefore, these methods can be used to investigate both the functional
significance of genomic variation as well as to identify alterations in genome activity and
sequence composition associated with a treatment or disease. Of note, as is the case in transcriptome sequencing, these methods of capturing information on genome function only
reveal information about the genome’s activity within the tissue or cell population sampled
at time of sampling.
Data Generation and Handling
For most any platform, the process of sequencing is similar. The general workflow of an
NGS experiment is presented in Figure 3. The goals for interpretation and application of
the data generated can result in alterations of this general approach. The sample necessary
depends on the question at hand. For gene expression, RNA must be isolated from a tissue
relevant to the phenotype of interest. Because RNA is relatively unstable, care has to be
taken to either preserve the sample in an RNA-stabilization solution (e.g., RNAlater,
Sigma-Aldrich, St Louis, Missouri; DNA/RNA Shield, Zymo Research, Irvine, California)
or the tissue must be flash-frozen immediately after collection until processing. ChIP data
can also be derived from a flash-frozen sample or from samples subjected to a cross-linking
protocol, commonly performed with formaldehyde, at the time of collection. If the goal is
to identify genomic variation, genomic DNA must first be isolated from a sample of the
individual. Blood and tissue are commonly used samples for DNA isolation, although hair
follicles can also produce adequate DNA for sequencing of target genes or the whole genome. The isolated DNA is hydrolyzed or sheared to create fragments of similar size and
is processed for library preparation. Methods for library preparation are conceptually similar, although there are platformspecific processes to make the input nucleic acid ready for
sequencing on a particular instrument. Barcode sequences can be included and allow individual samples to be pooled in a single sequencing run.

Figure 3. General workflow of an NGS experiment.

The general features of NGS data analysis are similar regardless of the platform used
to generate the data (Fig. 4). The data received from most sequencing methods are in the
form of fastq files. These files encode both the sequence identity of each read as well as an
associated quality metric. Data processing then involves an initial step of quality control
where any adapter sequences necessary for library preparation are removed, and the
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sequence is also trimmed to eliminate base calls that do not meet a designated quality
threshold. It is standard for the 3′ end of each read to be of lesser quality than the 5′ end,
and thus much of the trimming occurs on this portion of the read. If a paired-end library
is sequenced, it is important that the data from the 2 ends of each pair remain associated;
if 1 read is completely removed because of poor quality, its paired read must also be removed from the dataset. Once the data are preprocessed for quality control, the reads are
aligned with the equine reference genome, or possibly the transcriptome (in the case of
RNA-seq efforts). This process is computationally expensive and, depending on available
computing resources and amount of data being processed, it could take days to weeks.
However, the aligned reads (in bam files) can be visualized in software such as the Integrative Genomics Viewer51–53 or JBrowse.54

Figure 4. General features of NGS data analysis. CNV, copy number variation; INDEL,
insertion/deletion; SNPs, single nucleotide polymorphisms.

Once the sequencing reads are aligned, variants within the newly sequenced individual
and between it and the reference genome can be identified. Variant calling identifies single
nucleotide polymorphisms (SNPs), insertions/deletions, or structural variation that differ
between each individual and the reference genome, within an individual (i.e., heterozygous sites), or between study individuals. A variety of variant calling software is available
and has been reviewed elsewhere.55,56 The choice of a variant caller depends to some extent
on the question asked (e.g., rare variant identification vs. population frequency). In addition to the selection of variant calling software, the quality of the output also depends on
the depth of sequence coverage, sequence quality, and ability to filter false-positive signals.
Once variants are identified, the genome annotation provides a means to predict the functional impact (e.g., nonsynonymous mutation or splice-site variant) of each. For cases with
apparent simple inheritance, several databases exist to help identify candidate genes, or
genes previously associated with similar phenotypes. Online Mendelian Inheritance in
Man (OMIM; https://www.omim.org/), and Online Mendelian Inheritance in Animals (OMIA;
https://omia.org/home/) provide information on thousands of known mendelian traits.
Previously annotated variants and quantitative trait loci (loci associated with complex disease) are also often cataloged and can serve as valuable resources when investigating putative functional variation; these are available in databases such as the European Variation
Archive (https://www.ebi.ac.uk/eva/). However, not all variants or genes with an essential
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physiologic function are annotated as such. In contrast, not all loci computationally predicted or modeled to affect gene or protein function necessarily do so. Validation of function of a variant requires significant subsequent work beyond their discovery.
For transcriptomic data, variants can be called in a manner similar to that used for
whole-genome sequencing. However, the purpose of RNA-seq is often not to identify variation but altered expression of gene expression between affected versus unaffected tissues. Differential expression analyses are conducted based on the quantification of reads
observed per transcript. Data must first be normalized to account for differences in sequencing depth, and, depending on the method used, analyses may also consider transcript length. Reviews of methods for quantification and differential expression analyses
of RNA-seq data outline the statistical models used and assumptions underlying each approach.57,58 Transcriptomic data are often used to investigate the function of putative causative variants or to identify gene pathways associated with disease, such as in the case of
stationary night blindness of Appaloosas35 and Arabian cerebellar abiotrophy.59
Validation of Results
Even though NGS is becoming common, there are currently no standards set forth by the
veterinary industry on the interpretation or use of DNA sequencing or RNA-seq data.
Therefore, in the use of genetic or genomic information for equine management the onus
is on researchers, clinicians, owners, or other end users to evaluate the process by which
the data were discovered and validated. In human medicine, various interest groups, such
as the Next-Generation Sequencing: Standardization of Clinical testing II informatics
workgroup60 and the American College of Medical Genetics and Genomics,61 have worked
to address the means to ensure that rigorous standards of variant discovery and validation
are met. Some of the principles put in place by these entities include outlining a vocabulary
useful to classify variant function and assist clinicians in using information regarding genetic tests in practice.60,61 Another idea shared by both groups emphasizes that variant
function and predictive ability need to be validated in individuals unique to those used in
the discovery process and the variant frequency within the population (e.g., breed in the
case of horses) should be described. Toward a similar goal of standardizing how genomics
research is implemented, validated, and applied, the international equine genomic research community recently put forth a “Consensus Statement on the Translation and Application of Genomics in the Equine Industry” (Havemeyer Principles 2019: https://horse
genomeworkshop.com/values).62 In this statement, the researchers acknowledge that genomics and discovery using NGS holds significant promise to improve equine well-being.
However, with the complexity of disease and of genome function, the community agreed
the most significant benefit of genomics to the horse lies in discovery that encompasses
several key elements. These elements include ensuring that genomic research is reproducible and peer reviewed, ethical, and performed and communicated with transparency. As
the use of NGS increases, these guidelines will need to become more clearly defined because, although the potential for genomics to improve equine health and well-being is undeniable, its successful application also depends on the rigor of the research behind the
discoveries.
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Future Directions
The degree of advancement of genomic tools for researchers and clinicians in the past 10
years has been tremendous. The accelerated rate of discovery is likely to continue, and,
with decreasing costs of NGS, the use of this method in the diagnosis, prevention, and
management of disease is likely to become common practice. As researchers build a better
understanding of how genetic variation alters an individual’s ability to respond to treatment or optimize performance, the idea of personalized or precision management for horses
is far reaching. In addition, a greater understanding of genomic relationships among individuals, as well as how genomic variation contributes to complex phenotypes such as disease, lends itself to use in genomic selection, or the incorporation of genomic information
with phenotype data to predict an animal’s breeding value for a trait or traits of interest.
The improved understanding of genome function and disease susceptibility supported by
the application of NGS can lead to better horse health and welfare.
Disclosure – The authors have nothing to disclose.
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